American Well Co. (NYSE:AMWL) Receives Average Recommendation of “Hold” from Analysts

Shares of American Well Co. (NYSE:AMWL) have received a consensus recommendation of “Hold” from the six ratings firms that are currently covering the company, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $11.90.

A number of equities analysts have weighed in on AMWL shares. Needham & Company LLC reaffirmed a “hold” rating on shares of American Well in a research note on Thursday. Truist Financial boosted their target price on shares of American Well from $10.00 to $12.00 and gave the stock a “hold” rating in a research note on Friday. Stifel Nicolaus lifted their price target on shares of American Well from $9.00 to $10.00 and gave the stock a “hold” rating in a research report on Thursday. Morgan Stanley lowered their price target on shares of American Well from $20.00 to $10.50 and set an “equal weight” rating for the company in a research report on Tuesday, December 17th. Finally, Wells Fargo & Company upgraded shares of American Well from an “equal weight” rating to an “overweight” rating and set a $15.00 price target for the company in a research report on Monday, January 13th.

American Well Stock Up 3.2 %

NYSE AMWL traded up $0.38 during midday trading on Friday, hitting $12.11. The company had a trading volume of 105,781 shares, compared to its average volume of 64,409. The firm has a fifty day simple moving average of $9.26 and a two-hundred day simple moving average of $9.14. American Well has a fifty-two week low of $5.00 and a fifty-two week high of $29.00. The stock has a market cap of $185.53 million, a price-to-earnings ratio of -0.83 and a beta of 1.18.

American Well (NYSE:AMWL) last announced its quarterly earnings results on Wednesday, February 12th. The company reported ($2.77) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.04) by $0.27. American Well had a negative net margin of 84.27% and a negative return on equity of 52.49%. As a group, equities analysts predict that American Well will post -13.38 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Senvest Management LLC boosted its holdings in shares of American Well by 3.9% in the fourth quarter. Senvest Management LLC now owns 1,300,611 shares of the company’s stock valued at $9,429,000 after buying an additional 48,800 shares during the period. Geode Capital Management LLC boosted its holdings in shares of American Well by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 147,925 shares of the company’s stock valued at $1,073,000 after buying an additional 922 shares during the period. Norges Bank acquired a new position in shares of American Well in the fourth quarter valued at approximately $204,000. Takeda Pharmaceutical Co. Ltd. acquired a new position in shares of American Well in the fourth quarter valued at approximately $564,000. Finally, Compagnie Lombard Odier SCmA acquired a new position in shares of American Well in the fourth quarter valued at approximately $45,000. Institutional investors and hedge funds own 56.05% of the company’s stock.

About American Well

American Well Corporation, an enterprise platform and software company, delivers digitally enabling hybrid care in the United States and internationally. The company offers Converge, a cloud-based platform that enables health providers, payers, and innovators to provide in-person, virtual and automated care; and delivers virtual primary care, post-discharge follow-up, chronic condition management, virtual nursing, e-sitting, on-demand and scheduled virtual visits, specialty consults, automated care, and behavioral health, as well as specialty care programs, including dermatology, musculoskeletal care, second opinion, and cardiometabolic care to patients and members.